Oil prices hold steady as investors monitor Russia-Ukraine ceasefire talks
Futures buoyant, dollar drifts as markets sail toward tariff storm
Re-election pledges to tip Australian budget back into red
South Korea's Constitutional Court strikes down impeachment of PM Han Duck-soo
Golf-Woods makes it official, announces relationship with Vanessa Trump
Better eat your Wheaties? Kentucky's Amari Williams credits Weetabix instead for his big game
Derik Queen's buzzer-beating fadeaway gives Maryland a 72-71 March Madness win over Colorado State
COPENHAGEN (Reuters) - Novo Nordisk is lifting curbs on prescriptions of its weight-loss drug Wegovy in the United States and is increasing supply in that market, its CEO said on Wednesday.
"In our guidance for the full year, you can assume that there is a step up in the fourth quarter and that's partly driven by increased products including Wegovy into the U.S.," Lars Fruergaard Jorgensen told Reuters in an interview.
He said that the slower pace of weekly prescriptions for Wegovy in the United States in the last couple of months was due to lower starter doses being supplied into the market.
"You can find different periods of times where you can say it's plateauing but it's not because of plateaued demand, it's simply because of the supply into the market," Fruergaard said.
(Reporting by Jacob Gronholt-Pedersen, Editing by Louise Heavens)
